Equibles does not estimate personal net worth.
Get an email with a short summary when Revolution Medicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get RVMD alertsAlan Sandler is recorded as Board Member at Alx Oncology Holdings Inc (ALXO). The newest filing on record that lists Alan Sandler as Board Member at Alx Oncology Holdings Inc (ALXO) is dated April 20, 2026. Zai Lab Ltd reported in an 8-K filed October 28, 2022 that Alan Sandler resigned as Dr. Alan Sandler, effective October 28, 2022. Alan Sandler has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Revolution Medicines, Inc. on August 5, 2026. Revolution Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Alx Oncology Holdings Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Revolution Medicines, Inc. includes Mark Goldsmith (CEO and Board Member), Jack Anders (CFO), Margaret Horn (COO) and 7 others.
“On October 24, 2022, Zai Lab Limited (the "Company") entered into a Severance Agreement and General Release (the "Agreement") with Dr. Alan Sandler who provided notice that he is resigning from the Company, effective October 28, 2022, to pursue another professional opportunity.”
“While pancreatic cancer remains an important and immediate opportunity for revolution medicines, non-small cell lung cancer represents another major malignancy where despite meaningful advances in treatment, significant unmet needs remain.”
“I just want to add to exactly what Wei had said and just emphasize that the point that you had made that the more experienced physicians have with Diraxxon RACIV, the better they are in terms of anticipating and treating the rash in addition our medical affairs groups will be coming up with standardized approaches for…”
“Well, I think we've set up very nicely with multiple studies to kind of have a major say as to what pancreatic cancer will look like in the next three to five years, you know, with our early studies looking at second-line therapy with Diraxxon-Rasiv, moving into the first-line setting also with Diraxxon-Rasiv, looking…”
Proxy statement
Start not stated–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 20, 2026
Proxy statement
Start not stated–2025-04-21
Last confirmed by a filing; no departure on record
Source not stated
Start not stated–2022-10-28
Start not stated–2024-11-10
Biotechnology · Healthcare
